# Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy

> **NCT07561060** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 50 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07561060
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2027-12
- **Final completion:** 2028-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07561060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07561060, "Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07561060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*